
Product Data Sheet

Product Name: Emactuzumab

Cat. No.: GC66380

Chemical Properties

Cas. No. 1448221-67-7

Formula M.Wt 144.4kDa

Solubility Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

IC50: 0.2 nM (CSF-1R)^[2]

Emactuzumab(RG 7155) is a specific **monoclonal antibody** that inhibits colonystimulating factor 1 receptor (**CSF1R**) activation. Emactuzumab has high affinity for CSF-1R with **K_i** value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) ^{[1][2]}.

Emactuzumab (RG 7155) binds to human and cynomolgus CSF-1R with high affinity (K_d = 0.2 nM) to blocks CSF-1R dimerization^[2].

RG7155 (0-10 µg/mL, 7 days) potently inhibited the viability of CSF-1-differentiated macrophages with an IC₅₀ of 0.3 nM by inducing cell death^[2].

RG7155 (30 µg/mL, 6 days) induces cell death of in vitro-differentiated human M2-like macrophages^[2].

Cell Viability Assay^[2]

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Cell Line: CSF-1 and/or GM-CSF Macrophages

Concentration: 0-10 µg/mL

Incubation Time: 7 days

Result: Resulted cell death of CSF-1-differentiated macrophages.

Emactuzumab(RG 7155) (i.v.; 0.1, 1, 10, 30 and 100 mg/kg; once) increases CSF-1 concentration in nonhuman primates' peripheral blood^[2].
RG7155 (i.v.; 0, 30, and 100 mg/kg; once weekly; for 2 weeks) depletes CSF-1R⁺CD163⁺ macrophages in vivo^[2].

Animal Model: cynomolgus monkeys *Macaca fascicularis*^[2]

Dosage: 0.1, 1, 10, 30 and 100 mg/kg (male cynomolgus monkeys), 0, 30, and 100 mg/kg (male and female cynomolgus)

Administration: i.v., once (male cynomolgus monkeys) i.v., once weekly, for 2 weeks (male and female cynomolgus)

Result: Increased CSF-1 concentration in serum. Efficiently reduced CSF-1R and CD68⁺163⁺ macrophages in the liver (Kupffer cells) and colon of cynomologus monkeys.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA
